Curium Gains FDA Approval for BEXLUTRY in GEP-NETs
BOSTON, Mass. — September 14, 2026 Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its...
radioligand therapy
Advertisement
TwoStep Therapeutics Secures $62.5M and FDA IND Clearance
SAN CARLOS, Calif. — September 9, 2026 TwoStep Therapeutics announced an oversubscribed $62.5 million Series A financing alongside U.S....
GE HealthCare Advances StarGuide GX for Theranostics
CHICAGO — September 8, 2026 GE HealthCare announced that its new StarGuide GX digital 4D CZT SPECT/CT system is...
Curium to Merge with Lantheus in $8B Radiopharma Deal
Boston & Bedford, Massachusetts, August 3, 2026 Curium and Lantheus Holdings, Inc. have entered into a definitive merger agreement...
Novartis’ Pluvicto Wins FDA Approval for Earlier Prostate Cancer Treatment
SILVER SPRING, Md., July 31, 2026 The U.S. Food and Drug Administration (FDA) has approved Novartis’ Pluvicto (lutetium Lu...
Advertisements
Ratio Therapeutics Raises $70 Million to Advance Radiotherapeutics
BOSTON, July 31, 2026 Ratio Therapeutics announced the successful closing of a $70 million Series C financing, increasing the...
Immunome Doses First Patient in Phase 1 IM-3050 Radioligand Therapy Trial
BOTHELL, Wash., July 20, 2026 Immunome, Inc. (Nasdaq: IMNM) announced that the first patient has been dosed in the...
C Ray Therapeutics Secures Key Radiopharmaceutical License
CHENGDU, China, June 2026 C Ray Therapeutics (Chengdu) Co., Ltd. announced that it has officially obtained a Radiopharmaceutical Manufacturing...
Teva Highlights Long-Term AUSTEDO Success in Tardive Dyskinesia Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
Curium Court Victory Clears Path for U.S. GEP-NET Therapy
BOSTON, MA, June 18, 2026 Curium™ has secured a significant legal and commercial milestone after prevailing in a patent...
Advertisement
